New York Drug Laws: Penalties, Charges & Treatment Options

New York drug laws are codified primarily in Penal Law Article 220 (Controlled Substances Offenses) and Public Health Law Article 33 (Controlled Substances). The state classifies controlled substances into five schedules (I through V) under Public Health Law § 3306, mirroring the federal Controlled Substances Act framework. Schedule I substances have the highest potential for abuse with no accepted medical use, while Schedule V substances have the lowest abuse potential.

New York's drug penalty structure uses a degree system ranging from seventh degree (the least serious, PL 220.03) to first degree (the most serious, PL 220.21 for possession, PL 220.43 for sale). Penalties are determined by the type of substance, weight or quantity, and whether the offense involves possession or sale. The state distinguishes between criminal possession (PL 220.03-220.21) and criminal sale (PL 220.31-220.43) of controlled substances, with sale offenses generally carrying more severe penalties.

New York's drug laws have undergone significant reform over the past two decades. The infamous Rockefeller Drug Laws of 1973, once among the harshest in the nation, were substantially reformed in 2004 and 2009 to eliminate mandatory life sentences, restore judicial discretion, and expand treatment alternatives. The 2021 Marihuana Regulation and Taxation Act (MRTA) legalized recreational cannabis, and ongoing legislative efforts continue to address the fentanyl crisis and expand harm reduction programs. The state has also enacted robust Good Samaritan protections and expanded naloxone access to combat opioid overdose deaths.

New York penalizes drug possession under Penal Law Article 220, using a seven-tiered degree system. The severity depends on the substance type, aggregate weight, and any intent to sell.

Seventh Degree (PL 220.03) — Class A Misdemeanor: Knowingly and unlawfully possessing any controlled substance in any amount. Punishable by up to 1 year in jail and a fine up to $1,000. This is the most commonly charged drug possession offense in New York and does not require a specific quantity threshold.

Fifth Degree (PL 220.06) — Class D Felony: Possession of specified substances above threshold amounts, such as 500 milligrams or more of cocaine, one-eighth ounce or more of heroin, or 25 milligrams or more of PCP. Also includes possession of controlled substances with intent to sell. Punishable by up to 7 years in prison.

Fourth Degree (PL 220.09) — Class C Felony: Possession of larger quantities, including one-eighth ounce or more of a narcotic drug, one ounce or more of methamphetamine, or specified quantities of LSD, stimulants, or hallucinogens. Punishable by up to 15 years in prison.

Third Degree (PL 220.16) — Class B Felony: Possession of one-half ounce or more of a narcotic drug, or possession of any narcotic drug with intent to sell. Punishable by 1 to 9 years in prison.

Second Degree (PL 220.18) — Class A-II Felony: Possession of four ounces or more of a narcotic drug, two ounces or more of methamphetamine, ten grams or more of a stimulant, twenty-five milligrams or more of LSD, or six hundred twenty-five milligrams or more of a hallucinogen. Punishable by 3 to 10 years for a first-time offender.

First Degree (PL 220.21) — Class A-I Felony: Possession of eight ounces or more of a narcotic drug in aggregate weight. This is one of the most serious felony classifications in New York. Mandatory minimum of 8 years (first offense), 12 years (one prior felony), or 15 years (two or more prior felonies), with a maximum of 20 years.

Important Note: Following the 2004 and 2009 Rockefeller Drug Law reforms, judges have restored discretion to impose alternatives to incarceration for many nonviolent drug possession offenses, including probation, treatment programs, and local jail sentences.

New York's impaired driving laws are found in Vehicle and Traffic Law (VTL) § 1192. Driving while impaired by drugs is addressed under VTL § 1192(4) (DWAI-Drugs) and VTL § 1192(4-a) (DWAI-Combined Influence of Alcohol and Drugs).

DWAI-Drugs — First Offense (Misdemeanor): Operating a motor vehicle while ability is impaired by a drug. Penalties include a fine of $500 to $1,000, up to 1 year in jail, 3 years of probation, 6-month license revocation, and mandatory surcharges of $395. Completion of a substance abuse evaluation and Drinking Driver Program (DDP) may be required.

DWAI-Drugs — Second Offense Within 10 Years (Class E Felony): A second DWAI-Drug conviction within 10 years of any DWAI conviction is automatically elevated to a Class E felony. Penalties include a fine of $1,000 to $5,000, up to 4 years in prison, and a minimum 1-year license revocation.

DWAI-Drugs — Third Offense Within 10 Years (Class D Felony): A third or subsequent conviction within 10 years is a Class D felony. Penalties include a fine of $2,000 to $10,000, up to 7 years in prison, and possible permanent license revocation if all offenses occurred within 4 years of each other.

DWAI-Combined Influence — VTL § 1192(4-a): Driving while impaired by the combined influence of alcohol and drugs carries the same penalty structure as DWAI-Drugs.

Implied Consent: Under VTL § 1194, any person operating a motor vehicle in New York is deemed to have given consent to chemical testing. Refusal to submit to testing results in an automatic 1-year license revocation and a $500 civil penalty for a first refusal.

Zero Tolerance for Under 21: VTL § 1192-a imposes zero tolerance for drivers under 21. Any BAC of .02 to .07 triggers license suspension and penalties. Drug impairment for under-21 drivers is prosecuted under the standard DWAI-Drugs statute.

Drug Recognition Experts: New York uses trained Drug Recognition Experts (DREs) to evaluate suspected drugged drivers. Since there is no per se legal limit for drug concentration in blood, impairment is established through DRE evaluations, field sobriety tests, and toxicology results.

New York has enacted some of the most comprehensive naloxone access laws in the nation to combat the opioid overdose crisis. The state's naloxone framework operates under multiple statutes including Public Health Law § 3309 and § 3000-a.

Pharmacy Access: Naloxone (Narcan) is available at pharmacies throughout New York State without an individual prescription. Pharmacists may dispense naloxone under a statewide non-patient-specific standing order. Any pharmacy chain with 20 or more locations in New York must either maintain a non-patient-specific prescription to dispense naloxone on request or register as an opioid overdose prevention program.

Opioid Overdose Prevention Programs (OOPPs): New York authorizes registered Opioid Overdose Prevention Programs to train laypersons and distribute naloxone kits. Over 700 OOPPs operate statewide, distributing hundreds of thousands of naloxone kits annually through community organizations, health departments, and harm reduction agencies.

Who Can Obtain and Administer: Any person who may be in a position to assist someone at risk of an opioid overdose can obtain naloxone — including family members, friends, first responders, shelter workers, and community members. Training is widely available but not legally required to obtain or administer naloxone.

Expanded Access (2024-2025): New York expanded the categories of entities authorized to possess, distribute, and administer naloxone to include retail bars, shopping malls, barber shops, beauty parlors, theaters, sporting venues, event centers, inns, and motels.

Civil Liability Protection: Under Public Health Law § 3000-a, any person who administers naloxone in good faith to someone experiencing an apparent opioid overdose is immune from civil liability for the administration.

Cost: Naloxone is available at no cost through many OOPPs and community distribution programs. When purchased through pharmacies, it is typically covered by insurance. New York Medicaid covers naloxone with no copay.

New York operates one of the largest and most established drug court systems in the United States. The state pioneered the drug court model, with the first modern drug court in the nation launched in Brooklyn in 1996 under the Drug Treatment Alternative to Prison (DTAP) program.

Scale: New York currently operates over 150 drug treatment courts across all 62 counties, including adult drug courts, juvenile drug courts, family treatment courts, DWI courts, and veterans treatment courts. The courts are coordinated by the New York State Unified Court System's Office of Policy and Planning.

Drug Treatment Alternative to Prison (DTAP): The Brooklyn DTAP model, now replicated across New York, uses a deferred-sentencing approach: defendants plead guilty to a felony but the prison sentence is deferred while participants enter 15 to 24 months of intensive residential drug treatment followed by aftercare services. Successful completers can withdraw their guilty plea and have the case dismissed. More than 52% of participants graduate, and research shows a 32% rearrest rate for DTAP participants versus 47% for the control group at 3-year follow-up. DTAP costs approximately $32,975 per participant compared to $64,338 for incarceration.

Eligibility: Drug courts generally serve nonviolent felony offenders whose criminal conduct is substantially motivated by substance use disorders. Eligibility criteria vary by county but typically exclude defendants charged with violent felonies, sex offenses, or offenses involving firearms.

Program Components: Participants undergo frequent court appearances before a dedicated judge, random drug and alcohol testing, intensive substance use disorder treatment (individual and group counseling), case management, employment and education support, and graduated sanctions and incentives for compliance.

Judicial Diversion (CPL 216.05): New York's judicial diversion statute, Criminal Procedure Law § 216.05, authorizes judges to divert eligible defendants with substance use disorders into treatment as a condition of a plea or in lieu of incarceration, even outside of formal drug court programs.

New York's mandatory minimum sentencing for drug offenses has undergone dramatic reform since the original Rockefeller Drug Laws were enacted in 1973. Two major reform acts — the Drug Law Reform Act of 2004 and the Drug Law Reform Act of 2009 — substantially reduced mandatory minimums and restored judicial discretion.

Current Mandatory Minimums for A-I Felonies (PL 220.21, PL 220.43): The most serious drug offenses — first-degree possession (8+ ounces of narcotics) and first-degree sale (2+ ounces of narcotics) — carry a mandatory minimum of 8 years in prison for first-time offenders (reduced from 15 years to life under the original Rockefeller Laws). For defendants with one prior felony drug conviction, the minimum is 12 years. For those with two or more prior felonies, the minimum is 15 years. Maximum sentence is 20 years.

A-II Felonies (PL 220.18, PL 220.41): Second-degree possession and sale carry a mandatory minimum of 3 years for first-time offenders, with a maximum of 10 years. Prior felony convictions increase the minimum to 6 years (one prior) or 8 years (two or more priors).

2009 Reform — Elimination of Most Mandatory Minimums: The 2009 Drug Law Reform Act eliminated mandatory minimum prison sentences for most drug offenses below the A-I and A-II felony level. Judges now have discretion to impose probation, local jail, treatment, or other alternatives for Class B through D felony drug offenses. This was the most significant change, restoring judicial discretion that had been removed by the original Rockefeller Laws.

Resentencing: Both the 2004 and 2009 reforms provided resentencing opportunities for individuals incarcerated under the old Rockefeller Drug Laws. Thousands of inmates applied for and received reduced sentences under these provisions.

Predicate Felony Enhancements: Under Penal Law § 70.70, second felony drug offenders face enhanced minimum sentences. The court must impose a determinate sentence, and the minimum cannot be less than the statutory floor for the offense class.

New York provides extensive pathways for diverting drug offenders from incarceration to treatment, reflecting the state's post-Rockefeller reform philosophy of treating addiction as a public health issue.

Judicial Diversion (CPL 216.05): Criminal Procedure Law § 216.05 authorizes judges to divert eligible defendants diagnosed with substance use disorders into court-supervised treatment programs. If the defendant successfully completes treatment, the court may dismiss the charges, reduce the conviction, or impose a non-incarceratory sentence. This is available for most nonviolent felony drug offenses.

Drug Treatment Alternative to Prison (DTAP): Operated by district attorneys' offices, DTAP diverts repeat nonviolent felony offenders into 15-24 months of intensive residential treatment. Successful completion results in charge dismissal or reduction. DTAP graduates are 3.5 times more likely to be employed than before arrest.

Drug Courts: Over 150 drug treatment courts statewide provide structured treatment programs as alternatives to incarceration, with graduated sanctions and rewards for compliance. See Drug Courts section for details.

Willard Drug Treatment Campus: The Willard Drug Treatment Campus (operated by DOCCS) provides a 90-day intensive residential substance abuse treatment program for state-sentenced drug offenders as an alternative to longer prison terms. Upon completion, participants are released to community supervision.

TASC (Treatment Alternatives for Safer Communities): TASC programs operate in many New York counties, providing screening, assessment, referral, case management, and monitoring services to connect justice-involved individuals with community-based treatment.

OASAS-Certified Treatment: The New York State Office of Addiction Services and Supports (OASAS) certifies and funds a comprehensive continuum of substance use disorder treatment, including crisis services, inpatient/residential treatment, outpatient programs, opioid treatment programs (methadone/buprenorphine), and recovery support services. Courts routinely order participation in OASAS-certified programs as conditions of probation or diversion.

Probation and Conditional Discharge: Following the 2009 reforms, judges have broad discretion to impose probation with mandatory treatment conditions for most drug felonies below the A-I and A-II level, avoiding incarceration entirely for treatment-amenable offenders.

New York has enacted several significant changes to its drug laws between 2021 and 2025:

2021 — Marihuana Regulation and Taxation Act (MRTA): Signed on March 31, 2021, the MRTA legalized recreational cannabis for adults 21+, created the Office of Cannabis Management and Cannabis Control Board, authorized possession of up to 3 ounces of flower and 24 grams of concentrate, permitted home cultivation, directed 50% of tax revenue to a Community Grants Reinvestment Fund for disproportionately affected communities, and provided for automatic expungement of past marijuana convictions for offenses no longer criminalized.

2022-2023 — Cannabis Market Launch: Legal retail cannabis sales began December 29, 2022. The state licensed Conditional Adult-Use Retail Dispensaries (CAURD), prioritizing applicants with prior marijuana convictions or their family members. By 2024, total sales exceeded $1 billion with nearly 300 dispensaries operating statewide.

2023 — Clean Slate Act: Enacted in 2023, the Clean Slate Act will automatically seal conviction records for eligible individuals who have completed their sentences and remained conviction-free — 3 years for misdemeanors, 8 years for felonies. Full implementation is expected by 2027. This law will significantly benefit individuals with past drug convictions seeking employment and housing.

2024-2025 — Expanded Naloxone Access: New York expanded the categories of businesses and establishments authorized to possess and distribute naloxone to include bars, shopping malls, barber shops, beauty parlors, theaters, sporting venues, and hotels, reflecting the continued urgency of the opioid crisis.

2025 — Pending Fentanyl Legislation: Multiple bills have been introduced in the 2025 legislative session to create fentanyl-specific criminal penalties, including proposals to classify possession of 500+ milligrams of fentanyl as a fifth-degree felony (S5376), define fentanyl analogues for prosecution purposes (S3934), and create standalone fentanyl distribution offenses (S2096). As of early 2025, these bills remain pending in committee.

Ongoing — Illicit Cannabis Enforcement: The state has increased enforcement against unlicensed cannabis shops, with the OCM and local law enforcement conducting padlock operations against illegal dispensaries that proliferated ahead of the legal market's rollout.